Funding for this research was provided by:
Helmholtz-Gemeinschaft (ICEMED 'Imaging and Curing Environmental Metabolic Diseases' Alliance, Initiative and Networking Fund, Helmholtz-Israel-Cooperation in Personalized Medicine, Portfolio Program Metabolic Dysfunction, Personalized Medicine Initiative)
Alexander von Humboldt-Stiftung
Received: 21 August 2017
Accepted: 22 January 2018
First Online: 8 February 2018
: All studies in mice were approved by and performed according to the guidelines of the State of Bavaria, Germany.
: Not applicable.
: Matthias Tschöp is a scientific advisor to Novo Nordisk and ERX.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.